Endonovo
Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive
Electroceutical(R) therapeutic devices, on Thursday announced its filing of a
preliminary information statement with respect to a proposed reverse stock
split of its common stock at a ratio of between 1 for 100 and 1-for-1,000.
According to the update, the proposed reverse stock split effectiveness is
contingent upon final SEC clearance of the Information Statement, mailing of
the statement and a twenty-day waiting period, Endonovo’s sole director’s
decision as to the final ratio of the reverse stock split, filing of a
certificate of amendment to the company’s certificate of incorporation, and review
of the proposal by FINRA. “This reverse stock split is an important step in our
future and our goal for growing the company and creating long-term shareholder
value and attracting a broader, more diverse shareholder base, especially in
light of the SofPulse(R) sales and our national rollout,” Endonovo Therapeutics
CEO Alan Collier said in the news release.
To view the full press release, visit http://ibn.fm/6l2M3
About Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of
noninvasive, wearable Electroceuticals(R) therapeutic devices. The company’s
current portfolio of commercial and clinical-stage wearable Electroceuticals(R)
therapeutic devices addresses wound healing, pain, postsurgical pain and edema,
cardiovascular disease, chronic kidney disease, and central nervous system
(“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions,
post concussion syndrome and multiple sclerosis. The company’s noninvasive Electroceutical(R)
therapeutic device, SofPulse(R), which uses pulsed short-wave radiofrequency at
27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of
soft-tissue injuries and postoperative pain and edema and has CMS national
coverage for the treatment of chronic wounds. The company’s current portfolio
of preclinical-stage Electroceuticals(R) therapeutic devices addresses chronic
kidney disease, liver-disease nonalcoholic steatohepatitis (NASH),
cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The
company’s noninvasive, wearable Electroceuticals(R) therapeutic devices work by
restoring key electrochemical processes that initiate anti-inflammatory and
growth-factor cascades necessary for healing to occur. For more information,
visit the company’s website at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates
relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment